Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BLRX |
---|---|---|
09:32 ET | 10996 | 0.6695 |
09:36 ET | 1861 | 0.6701 |
09:39 ET | 1100 | 0.6751 |
09:45 ET | 1300 | 0.6751 |
09:50 ET | 9200 | 0.6675 |
09:54 ET | 750 | 0.675 |
09:56 ET | 253 | 0.675 |
09:59 ET | 500 | 0.6675 |
10:01 ET | 1150 | 0.66 |
10:08 ET | 700 | 0.6671 |
10:10 ET | 7508 | 0.66 |
10:14 ET | 843 | 0.67237 |
10:15 ET | 3193 | 0.6681 |
10:19 ET | 3100 | 0.6681 |
10:24 ET | 100 | 0.6742 |
10:28 ET | 2300 | 0.6681 |
10:32 ET | 1100 | 0.6682 |
10:37 ET | 100 | 0.6711 |
10:39 ET | 100 | 0.6742 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
BioLine RX Ltd | 54.9M | -0.9x | --- |
Kronos Bio Inc | 57.1M | -0.6x | --- |
LAVA Therapeutics NV | 58.1M | -2.2x | --- |
Kezar Life Sciences Inc | 52.4M | -0.5x | --- |
Dyadic International Inc | 61.4M | -7.6x | --- |
Dare Bioscience Inc | 48.5M | -1.5x | --- |
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $54.9M |
---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.55 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 4.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.